Kura Oncology (NASDAQ:KURA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Friday, Benzinga reports. They currently have a $32.00 price objective on the stock.

A number of other equities research analysts have also recently commented on the stock. StockNews.com cut shares of Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. Wedbush reaffirmed an outperform rating and set a $37.00 price target on shares of Kura Oncology in a research note on Friday. Finally, JMP Securities boosted their price objective on Kura Oncology from $22.00 to $32.00 and gave the company a market outperform rating in a report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $28.28.

Kura Oncology Trading Up 0.2 %

Shares of KURA stock traded up $0.04 during mid-day trading on Friday, hitting $20.63. The company’s stock had a trading volume of 605,625 shares, compared to its average volume of 831,868. The company has a market cap of $1.57 billion, a PE ratio of -9.51 and a beta of 0.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.26 and a current ratio of 12.26. The company’s fifty day simple moving average is $20.66 and its 200-day simple moving average is $15.94. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period last year, the business earned ($0.50) earnings per share. The business’s quarterly revenue was up .0% compared to the same quarter last year. As a group, equities research analysts expect that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC increased its position in shares of Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after acquiring an additional 1,449 shares during the last quarter. Pale Fire Capital SE purchased a new position in shares of Kura Oncology in the 3rd quarter worth about $92,000. E Fund Management Co. Ltd. grew its position in Kura Oncology by 12.2% during the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after buying an additional 1,301 shares during the period. AXQ Capital LP purchased a new stake in Kura Oncology during the third quarter worth about $118,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Kura Oncology by 352.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after acquiring an additional 6,692 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.